Thera-SAbDab

ECULIZUMAB

>   Structural Summary
TherapeuticEculizumab
TargetC5
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK
100% seqID Fv Structure5i5k [Fvs: HL, XY]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyGS Gene Expression System
INN Year Proposed2002
INN Year Recommended2003
Companies InvolvedAlexion Pharmaceuticals, Brigham and Womens Hospital, Chiba University, Handok Inc
Conditions ApprovedHaemolytic uraemic syndrome, Myasthenia gravis, Paroxysmal nocturnal haemoglobinuria
Conditions ActiveNeuromyelitis optica, Delayed graft function, Guillain-Barre syndrome, Renal transplant rejection
Conditions DiscontinuedAntiphospholipid syndrome, Heart transplant rejection, Adult respiratory distress syndrome, Age-related macular degeneration, Allergic asthma, Autoimmune haemolytic anaemia, Bullous pemphigoid, Dermatomyositis, Glomerulonephritis, Idiopathic thrombocytopenic purpura, Lupus nephritis, Membranous glomerulonephritis, Motor neuron disease, Psoriasis, Rheumatoid arthritis, Systemic lupus erythematosus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]